Our unique poly-bile nanoparticle platform holds promise to replace injections and eliminate the challenges of oral delivery in a breakthrough nanopill technology. The pill protects drugs, including biologics, through the stomach and intestines while retaining bioactivity. At the intestinal wall, the nanoparticles are taken into the body and enter circulation, where the drug is released.
CMax Oral to IV
Toralgen is a preclinical stage biopharmaceutical company focused on the development and commercialization of human therapeutics, currently studying treatments for diabetes and autoimmune disorders. Our executive team has a century and a half of combined experience in pharmaceutical research, development, and commercialization. The company is well-funded and welcoming pharmaceutical partners for upcoming trials.